Department of Biomedical Engineering, The State University of New Jersey, Piscataway, New Jersey, USA
Department of Pharmacy, Indira Gandhi National Tribal University (IGNTU), Amarkantak, India
Curr Neuropharmacol. 2020;18(11):1092-1105. doi: 10.2174/1570159X18666200522203542.
Traumatic injury to the spinal cord (SCI) and brain (TBI) are serious health problems and affect many people every year throughout the world. These devastating injuries are affecting not only patients but also their families socially as well as financially. SCI and TBI lead to neurological dysfunction besides continuous inflammation, ischemia, and necrosis followed by progressive neurodegeneration. There are well-established changes in several other processes such as gene expression as well as protein levels that are the important key factors to control the progression of these diseases. We are not yet able to collect enough knowledge on the underlying mechanisms leading to the altered gene expression profiles and protein levels in SCI and TBI. Cell loss is hastened by the induction or imbalance of pro- or anti-inflammatory expression profiles and transcription factors for cell survival after or during trauma. There is a sequence of events of dysregulation of these factors from early to late stages of trauma that opens a therapeutic window for new interventions to prevent/ restrict the progression of these diseases. There has been increasing interest in the modulation of these factors for improving the patient's quality of life by targeting both SCI and TBI. Here, we review some of the recent transcriptional factors and protein biomarkers that have been developed and discovered in the last decade in the context of targeted therapeutics for SCI and TBI patients.
脊髓损伤 (SCI) 和脑损伤 (TBI) 是严重的健康问题,每年在全球范围内都会影响许多人。这些毁灭性的损伤不仅影响患者,还会影响他们的家庭在社会和经济方面。SCI 和 TBI 除了持续的炎症、缺血和坏死外,还会导致神经功能障碍,随后进行进行性神经退行性变。其他几个过程也发生了明确的变化,如基因表达和蛋白质水平,这些都是控制这些疾病进展的重要关键因素。我们还没有收集到足够的知识来了解导致 SCI 和 TBI 中基因表达谱和蛋白质水平改变的潜在机制。细胞丢失是由促炎或抗炎表达谱和细胞存活的转录因子的诱导或失衡加速的,在创伤后或创伤期间,这些因素的失调会有一个从早期到晚期的连续事件,为新的干预措施打开了一个治疗窗口,以防止/限制这些疾病的进展。人们对这些因素的调节越来越感兴趣,通过针对 SCI 和 TBI 患者的靶向治疗来提高患者的生活质量。在这里,我们回顾了过去十年中在 SCI 和 TBI 的靶向治疗中开发和发现的一些最近的转录因子和蛋白质生物标志物。